DK1201639T3 - Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser - Google Patents

Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser

Info

Publication number
DK1201639T3
DK1201639T3 DK02001564T DK02001564T DK1201639T3 DK 1201639 T3 DK1201639 T3 DK 1201639T3 DK 02001564 T DK02001564 T DK 02001564T DK 02001564 T DK02001564 T DK 02001564T DK 1201639 T3 DK1201639 T3 DK 1201639T3
Authority
DK
Denmark
Prior art keywords
treatment
cell proliferative
proliferative disorders
lipoxin compounds
compounds
Prior art date
Application number
DK02001564T
Other languages
Danish (da)
English (en)
Inventor
Charles N Serhan
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK1201639T3 publication Critical patent/DK1201639T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
DK02001564T 1996-09-13 1997-09-15 Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser DK1201639T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/712,610 US6048897A (en) 1993-06-15 1996-09-13 Lipoxin compounds and their use in treating cell proliferative disorders
PCT/US1997/016342 WO1998011049A1 (en) 1996-09-13 1997-09-15 Lipoxin compounds and their use in treating cell proliferative disorders

Publications (1)

Publication Number Publication Date
DK1201639T3 true DK1201639T3 (da) 2008-11-24

Family

ID=24862848

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02001564T DK1201639T3 (da) 1996-09-13 1997-09-15 Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser
DK97941078T DK0927150T3 (da) 1996-09-13 1997-09-15 Lipoxinforbindelser og deres anvendelse til behandling af celleformeringsforstyrrelser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97941078T DK0927150T3 (da) 1996-09-13 1997-09-15 Lipoxinforbindelser og deres anvendelse til behandling af celleformeringsforstyrrelser

Country Status (11)

Country Link
US (9) US6048897A (US20020111505A1-20020815-C00030.png)
EP (3) EP2058293A1 (US20020111505A1-20020815-C00030.png)
JP (1) JP4060366B2 (US20020111505A1-20020815-C00030.png)
AT (2) ATE404522T1 (US20020111505A1-20020815-C00030.png)
AU (1) AU723321B2 (US20020111505A1-20020815-C00030.png)
CA (1) CA2265708C (US20020111505A1-20020815-C00030.png)
DE (2) DE69711894T2 (US20020111505A1-20020815-C00030.png)
DK (2) DK1201639T3 (US20020111505A1-20020815-C00030.png)
ES (2) ES2312499T3 (US20020111505A1-20020815-C00030.png)
PT (2) PT927150E (US20020111505A1-20020815-C00030.png)
WO (1) WO1998011049A1 (US20020111505A1-20020815-C00030.png)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US6887901B1 (en) * 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
CA2336807C (en) * 1998-07-08 2010-04-13 Aventis Pharma Deutschland Gmbh Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
CA2367909C (en) 1999-03-18 2008-02-12 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha) initiated neutrophil response
EP1616566A1 (en) * 1999-03-18 2006-01-18 The Brigham And Women's Hospital, Inc. Lipoxin compounds for treating TNF-alpha initiated inflammation
WO2000055109A1 (en) 1999-03-18 2000-09-21 Brigham And Women's Hospital Lipoxin compounds and their use
EP1586550A1 (en) * 1999-03-18 2005-10-19 The Brigham And Women's Hospital, Inc. Lipoxin compounds and their use
AU2004235617B2 (en) * 1999-03-18 2008-06-05 The Brigham And Women's Hospital, Inc. Lipoxin compounds and their use
ATE258791T1 (de) 1999-11-09 2004-02-15 Alcon Inc Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
CN1951899B (zh) 2000-02-16 2012-02-01 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
EP1268393A2 (en) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
ATE412448T1 (de) * 2001-03-02 2008-11-15 Brigham & Womens Hospital Lipoxin analoge als neue inhibitoren der angiogenese
ATE468157T1 (de) * 2001-03-02 2010-06-15 Brigham & Womens Hospital Lipoxinanaloge als neuartige restenose-hemmer
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
GB0119583D0 (en) * 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
WO2003039533A1 (en) * 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
EP1911448B1 (en) * 2001-11-06 2013-01-02 The Brigham and Women's Hospital, Inc. Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
EP1941875B1 (en) * 2001-12-18 2012-09-12 The Brigham and Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US7030159B2 (en) * 2001-12-18 2006-04-18 The Brigham And Women's Hospital, Inc. Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs
AU2002360660A1 (en) * 2001-12-18 2003-06-30 The Brigham And Women's Hospital, Inc. Use of lipoxin analogs to promote cell defense against gram-negative infections
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
EP3584235A3 (en) 2002-08-12 2020-04-22 Brigham and Women's Hospital Resolvins: biotemplates for novel therapeutic interventions
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
GB0313259D0 (en) * 2003-06-09 2003-07-16 Consejo Superior Investigacion Magnetic nanoparticles
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
CN101052387A (zh) * 2004-11-09 2007-10-10 爱尔康公司 用于治疗眼部疾病以及与过度增生和血管生成反应有关的疾病的5,6,7－三羟基庚酸及类似物
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US8245230B2 (en) * 2005-03-14 2012-08-14 Qnx Software Systems Limited Adaptive partitioning scheduler for multiprocessing system
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
US20100029504A1 (en) 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
JP2009515991A (ja) 2005-11-18 2009-04-16 トラスティーズ オブ ボストン ユニバーシティ レゾルビンを使用する骨喪失の処置および防止
US20070254897A1 (en) * 2006-04-28 2007-11-01 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
CL2007003468A1 (es) 2006-12-04 2008-07-04 Bayer Schering Pharma Ag Sal de potasio cristalina de analogos de lipoxina a4; metodode sintesis; composicion farmaceutica; y uso en el tratamiento de trastornos inflamatorios o autoinmunes.
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
JP2009026126A (ja) * 2007-07-20 2009-02-05 Nec Electronics Corp 半導体装置
CN101843622B (zh) * 2010-04-27 2011-09-14 黄波 脂氧素在制备女性避孕药物中的应用
WO2013056092A1 (en) 2011-10-12 2013-04-18 Case Western Reserve University Multi-component nanochains
EP2917738A1 (de) 2012-11-12 2015-09-16 BIOCRATES Life Sciences AG Verwendung von qualitätsindikatoren zum nachweis von auftauprozessen in gefrorenen gewebeproben
CN105439813B (zh) * 2014-08-08 2017-10-27 广州丹康医药生物有限公司 化合物的合成方法
KR102437682B1 (ko) 2016-06-03 2022-08-29 테티스 파마수티컬스 엘엘씨 특화된 사전 해소 매개체의 염에 관한 조성물 및 방법
WO2018098244A1 (en) * 2016-11-22 2018-05-31 The Brigham And Women's Hospital, Inc. Personalized metabolomic profiling of specialized pro-resolving mediators
US11439615B2 (en) 2017-03-09 2022-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2023168245A2 (en) 2022-03-03 2023-09-07 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560514A (en) * 1984-05-04 1985-12-24 Bengt Samuelsson Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds
US4576758A (en) * 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4780281A (en) 1985-06-14 1988-10-25 Wayne State University Method for assay of peroxidase enzyme or reducing substrate activity
JPS62198677A (ja) 1986-02-26 1987-09-02 Nissan Chem Ind Ltd テトラオ−ル誘導体
JPH0739368B2 (ja) 1986-10-01 1995-05-01 旭硝子株式会社 ２０，２０，２０−トリフルオロアラキドン酸誘導体およびその製造法
CA1329809C (en) * 1987-07-08 1994-05-24 Nissan Chemical Industries, Ltd. Optically active allyl alcohol and process for producing leucotriene b_ using thereof
JPH01228994A (ja) 1988-03-10 1989-09-12 Fumie Satou γ−シリルアリルアルコール及びその製造法
US5079261A (en) * 1989-04-28 1992-01-07 Brigham And Women's Hospital Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2834512B2 (ja) 1990-01-30 1998-12-09 帝人株式会社 リポキシン誘導体を有効成分とする疾患治療剤
US5322699A (en) 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JP3227922B2 (ja) 1993-01-20 2001-11-12 富士電機株式会社 自動販売機
US6048897A (en) * 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
JPH08512023A (ja) * 1993-06-15 1996-12-17 ブリガム・アンド・ウイメンズ・ホスピタル リポキシン化合物
AU7215294A (en) 1993-06-29 1995-01-24 Brigham And Women's Hospital Modulation of inflammation related to columnar epithelia
US5998487A (en) 1998-04-08 1999-12-07 Colgate-Palmolive Company Anti-inflammatory and antibacterial benzyl phenol agents and their use in oral compositions
EP1109553B1 (en) 1998-09-08 2006-04-26 Cornell Research Foundation, Inc. Use of cyclooxygenase-2 inhibitors for the treatment of inflammatory diseases of the head and neck
EP1268393A2 (en) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease

Also Published As

Publication number Publication date
CA2265708C (en) 2003-06-10
US6569075B2 (en) 2003-05-27
US6316648B1 (en) 2001-11-13
AU4271097A (en) 1998-04-02
EP0927150B1 (en) 2002-04-10
ES2312499T3 (es) 2009-03-01
CA2265708A1 (en) 1998-03-19
ATE404522T1 (de) 2008-08-15
PT927150E (pt) 2002-08-30
ES2175460T3 (es) 2002-11-16
EP0927150A1 (en) 1999-07-07
US20020111505A1 (en) 2002-08-15
DE69711894D1 (de) 2002-05-16
US6750360B2 (en) 2004-06-15
US6620919B2 (en) 2003-09-16
US20010031882A1 (en) 2001-10-18
WO1998011049A1 (en) 1998-03-19
US6048897A (en) 2000-04-11
US6635776B2 (en) 2003-10-21
EP1201639A2 (en) 2002-05-02
EP2058293A1 (en) 2009-05-13
DE69711894T2 (de) 2002-11-14
US20020082435A1 (en) 2002-06-27
EP1201639B1 (en) 2008-08-13
AU723321B2 (en) 2000-08-24
US20020091279A1 (en) 2002-07-11
DK0927150T3 (da) 2002-07-22
US20030134901A1 (en) 2003-07-17
EP1201639A3 (en) 2003-01-02
DE69738918D1 (de) 2008-09-25
JP2001500866A (ja) 2001-01-23
ATE215924T1 (de) 2002-04-15
US20030032827A1 (en) 2003-02-13
US6653493B2 (en) 2003-11-25
JP4060366B2 (ja) 2008-03-12
US20020010351A1 (en) 2002-01-24
PT1201639E (pt) 2008-10-03

Similar Documents

Publication Publication Date Title
DK1201639T3 (da) Lipoxinforbindelser og deres anvendelse til behandling af celleproliferative lidelser
DE69434218D1 (de) Photodynamische behandlung von synovium
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
DK0933995T3 (da) Fremgangsmåde til behandling af endotelskader
DK0703897T3 (da) Lipoxinforbindelser med forlænget halveringstid
DE69708121T2 (de) Halogenid-enthaltende insulinzubereitungen
DE69133022D1 (de) Viral verursachte Zerstörung von Neoplastzellen
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne
DK1702618T3 (da) Brug af ET743 i kombinationsterapi med dexamethason til behandling af cancer
DE69814394D1 (de) Verwendung von levobupivacain
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE317849T1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
IS5366A (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
BG101126A (en) The use of muramylpeptide compounds
DK0971710T3 (da) Anvendelse af chelerythrin og stråling til tumorterapi
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
JO2199B1 (en) Replaced pyrrols
ITTO20000441A0 (it) Composizione terapeutica per la cura della psoriasi.
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
DK0711163T3 (da) Anvendelse af benzydamin i behandlingen af patologiske tilstande forårsaget af TNF
DK1463541T3 (da) Biomaterialer baseret på hyaluronsyrebenzylester til anti-angiogen terapi i behandling af tumorer
UA8280A (uk) Спосіб лікування псоріазу
UA28400A (uk) Спосіб лікування мікробної екземи
UA22007A (uk) Спосіб лікуваhhя хроhічhого hеспецифічhого простатиту